The estimated Net Worth of Healthcare Capital Partners... is at least $47.8 Million dollars as of 17 January 2024. Healthcare Partners owns over 143,605 units of KalVista Pharmaceuticals Inc stock worth over $47,807,459 and over the last few years Healthcare sold KALV stock worth over $0.
Healthcare has made over 5 trades of the KalVista Pharmaceuticals Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently Healthcare bought 143,605 units of KALV stock worth $1,802,243 on 17 January 2024.
The largest trade Healthcare's ever made was buying 519,017 units of KalVista Pharmaceuticals Inc stock on 27 December 2023 worth over $6,466,952. On average, Healthcare trades about 177,187 units every 4 days since 2023. As of 17 January 2024 Healthcare still owns at least 4,459,651 units of KalVista Pharmaceuticals Inc stock.
You can see the complete history of Healthcare Partners stock trades at the bottom of the page.
Over the last 8 years, insiders at KalVista Pharmaceuticals Inc have traded over $74,823,944 worth of KalVista Pharmaceuticals Inc stock and bought 4,877,063 units worth $58,591,487 . The most active insiders traders include Holdings A/S Novo, Capital Management, L.P.Ra ..., and Rajeev M. Shah. On average, KalVista Pharmaceuticals Inc executives and independent directors trade stock every 19 days with the average trade being worth of $835,088. The most recent stock trade was executed by Benjamin L Palleiko on 6 September 2024, trading 15,625 units of KALV stock currently worth $167,500.
kalvista is a clinical stage pharmaceuticals company focused on the discovery, development, and commercialization of small molecule protease inhibitors.
KalVista Pharmaceuticals Inc executives and other stock owners filed with the SEC include: